Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
venerdì, ottobre 30
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Tarsus Pharmaceuticals Inc
TARS
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$74.85
0.65
0.88%
Ult. Agg.: Oct 30, 4:42 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Utili:
I risultati di Q3 2026 tra 4 giorni da adesso in mar nov 3rd, dopo la chiusura del mercato
Conference call:
Conference call programmata per tra 4 giorni alle 4:30 PM
Clicca per vedere il webcast
Tarsus Pharmaceuticals Financials
Tarsus Pharmaceuticals (TARS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Tarsus Pharmaceuticals Q2 EPS $(0.43) Misses $(0.20) Estimate, Sales $173.912M Beat $169.677M Estimate
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.20) by 115 percent. This is a 10.42 percent increase over losses of $(0.48) per
Benzinga Newsdesk
Earnings Scheduled For May 6, 2026
Benzinga Insights
PRO
Tarsus Pharmaceuticals Reaffirmed Full-year 2026 Guidance Of $670M-700M Of Xdemvy Net Product Sales And Peak Sales Potential Exceeding $2B
Benzinga Newsdesk
PRO
Tarsus Pharmaceuticals Q1 EPS $(0.16) Beats $(0.33) Estimate, Sales $162.054M Beat $148.422M Estimate
Benzinga Newsdesk
PRO
Tarsus Pharmaceuticals Q4 EPS $(0.20) Misses $(0.11) Estimate, Sales $151.668M Beat $144.565M Estimate
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.11) by 81.82 percent. This is a 66.67 percent increase over losses of $(0.60) per
Benzinga Newsdesk
Insights into Tarsus Pharmaceuticals Q4 Earnings
Benzinga Insights
